Perimenopause Is Not A Footnote
2026-08-11
Menopause is sold as a moment. Biology refuses that script. Perimenopause, the long hormonal transition that can stretch across many years, reshapes ovarian function, neuroendocrine feedback loops and daily life well before the final menstrual period. Hot flashes, insomnia, palpitations, joint pain, mood shifts and heavy or erratic bleeding often arrive while periods still appear, so symptoms are dismissed as stress, aging or anxiety disorders.
The blunt truth is that medicine still treats perimenopause as a side note. Clinical guidelines lean on the binary of fertile or not, while estradiol and follicle‑stimulating hormone swing wildly, confounding single blood tests that many clinicians still rely on. Research funding has lagged; large trials historically excluded midlife women, leaving gaps on cardiovascular risk, bone density loss and cognitive change during this transition. That neglect feeds a diagnostic vacuum where thyroid disease, depression or autoimmune flare are checked, yet fluctuating ovarian hormones are barely discussed.
Public conversation also flattens this phase into a joke about hot flashes. That narrative hides real inequities in work, caregiving and access to hormone therapy or nonhormonal treatments. Framing perimenopause as a discrete, study‑worthy stage would force changes: routine symptom screening in primary care, better longitudinal data on hypothalamic‑pituitary‑ovarian axis shifts, and workplace policies that assume midlife health is dynamic, not already settled.
Loading...
